Research of therapeutic effects of uterine artery embolization combined with drug therapy in treatment of uterus myoma

Abstract

Objective To explore the therapeutic effects of uterine artery embolization (UAE) combined with drug therapy in treatment of uterus myoma (UM). Methods From March 2012 to April 2013, a total of 40 cases of patients who were diagnosed as UM in Inner Mongolia Autonomous Region Chifeng Municipal Hospital and received treatments were selected into this study as research subjects. According to the treatment methods UM patients received, they were divided into study group (n=20, received UAE combined with uterine tumor eliminator capsule treatment) and control group (n=20, received UAE treatment alone). Adverse reactions after treatment and menstruation (menstrual cycle and period) and UM volume before treatment and 3, 6, 12 months after treatment of two groups were observed and were analyzed by statistical methods. There were no statistical differences between two groups among age, body weight, parity, gravidity, menstrual cycle and menstrual period and UM volume before treatment and so on (P>0.05). Results ①After treatment, the incidence of hypogastrium pain in study group was 5.0% (1/20) which was significantly lower than 35.0% (7/20) in control group, and the difference was statistically significant (χ2=5.625, P=0.018). While there were no statistical differences between two groups among the incidences of fever, nausea and vomiting, limb weakness and irregular vaginal bleeding (P>0.05). ②There was no interaction effect between group and time factor in menstrual cycles, and the difference was not statistically significant (Fgroup×time=0.593, P=0.555). There were no statistical differences among the menstrual cycles before and after treatment at different times (Ftime=0.103, P=0.902) and between two groups (Fgroup=0.057, P=0.813). There was interaction effect between group and time factor in menstrual period, and the difference was statistically significant (Fgroup×time=3.982, P=0.022). There were statistical differences among the menstrual periods before and after treatment at different times (Ftime=138.216, P=0.000) and between two groups (Fgroup=4.179, P=0.048). And 3, 6, and 12 months after treatment, the menstrual periods in two groups all were shorter than before treatment, and all the differences were statistically significant (study group: t=4.155, P=0.001; t=7.559, P=0.000; t=8.340, P=0.000; control group: t=3.075, P=0.006; t=6.155, P=0.000; t=6.373, P=0.000). Before treatment and 3 months after treatment, there were no statistical differences between two groups in menstrual periods (t=0.285, P=0.777; t=1.874, P=0.069), but 6 and 12 months after treatment, the menstrual periods in study group both were shorter than those in control group, and both the differences were statistically significant (t=3.079, P=0.004; t=2.539, P=0.015). As time increased, the menstrual period in study group shortened even higher than that in control group. ③There was interaction effect between group and time factor in UM volume, and the difference was statistically significant (Fgroup×time=7.853, P=0.001). There were statistical differences among the UM volume before and after treatment at different times (Ftime=494.861, P=0.000) and between two groups (Fgroup=6.971, P=0.012). Before treatment, there was no statistical difference between two groups in UM volume (t=0.032, P=0.975), while 3, 6 and 12 months after treatment, the UM volumes in study group all were smaller than those in control group, and all the differences were statistically significant (t=2.780, P=0.008; t=5.627, P=0.000; t=2.900, P=0.006). And 3, 6, and 12 months after treatment, the UM volumes in two groups all were smaller than before treatment, and all the differences were statistically significant (study group: t=7.982, P=0.000; t=13.617, P=0.000; t=17.889, P=0.000; control group: t=4.962, P=0.000; t=8.482, P=0.000; t=15.178, P=0.000). Conclusions UAE combined with uterine tumor eliminator capsule in treatment of UM can improve the menstruation of UM patients and reduce the volume of UM, and can effectively relieve hypogastrium pain caused by UAE, and then strengthen the therapeutic effects of UAE in treatment of UM. As the sample size in this study is small, the therapeutic effects of UAE combined with uterine tumor eliminator capsule in treatment of UM still remains to be confirmed by multicenter, large sample randomized controlled trials. Key words: Uterine artery embolization; Drug therapy; Myoma, uterus; Menstruation disturbances; Adverse reactions; Uterine tumor eliminator capsule